Bayer gets FDA nod for contrast with mammography

By staff writers

December 19, 2019 -- Contrast developer Bayer has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the use of its CT injectors for contrast-enhanced mammography applications.

The FDA nod applies to Bayer's Medrad Stellant Flex CT injectors used with the company's Certegra workstation software for contrast-enhanced mammography. Contrast mammography enables better visualization of breast abnormalities that might not normally be visualized on standard mammograms.

Bayer believes that using a contrast injection system like Stellant Flex provides benefits over manually administering contrast, such as accurate dose administration. The company notes that contrast-enhanced mammography has been shown to be more accurate than either standard mammography or breast ultrasound.

Copyright © 2019

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking